Encainida
Encainida Uses, Dosage, Side Effects, Food Interaction and all others data.
All drug products containing encainide hydrochloride. Encainida hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Used to treat irregular heartbeats, encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje system. Encainida decreases the rate of rise of the action potential without markedly affecting its duration.
Trade Name | Encainida |
Generic | Encainide |
Encainide Other Names | Encainida, Encainide, Encainidum |
Type | |
Formula | C22H28N2O2 |
Weight | Average: 352.4699 Monoisotopic: 352.21507815 |
Groups | Approved, Investigational, Withdrawn |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Encainida is a voltage-gated sodium channel blocker used for management of atrial or ventricular fibrillation, atrial flutter, and ventricular tachycardia, that is no longer used due to proarrhythmic adverse effects.
Encainida is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.
How Encainida works
Encainida is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
Half Life
1-2 hours
Elimination Route
A radiolabeled dose of encainide is excreted in approximately equal amounts in the urine and feces.
Innovators Monograph
You find simplified version here Encainida